- Details
- Description
Packaging Size:
1bottle/Box
Strength:
100mg(10ml)
Composition:
Enlonstobart
Treatment:
PD-L1 positive cervical cancer
Form:
Injection
Brand:
恩舒幸
Quantity Unit:
100mg(10ml)/Box
Manufacturer:
CSPC Pharmaceutical Group.,China
Enlonstobart, a recombinant, fully humanised immunoglobulin G4 monoclonal antibody targeted against programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.
- Enlonstobart sold under the brand name 恩舒幸 (Enshuxing) ® in china.
Enlonstobart received its first approval (a conditional marketing authorisation) in June 2024, in China, for use in patients with recurrent or metastatic programmed cell death ligand 1 (PD-L1)-positive cervical cancer who have failed previous platinum-containing chemotherapy.
